PRDM10 and cancer: Currently studies using integrated bioinformatics and network analysis have also recognized the role of PRDM10 in the onset, progression, and drug resistance of many malignancies, such as hepatocellular, prostate, and nasopharyngeal carcinoma, as well as gastric and rectum cancers [163,164,165,166,167,168]; although in our previous TGCA analysis, PRDM10 was either mutated or overexpressed in certain cancer types [45].